You are here

Article info

Article menu
Immunotherapy biomarkers
Original research
Peptide-based PET tracer targeting LAG-3 for evaluating the efficacy of immunotherapy in melanoma

Authors

  • Peizhe Yuan Department of Nuclear Medicine, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, ChinaHubei Province Key Laboratory of Molecular Imaging, Wuhan, ChinaKey Laboratory of Biological Targeted Therapy, the Ministry of Education, Wuhan, People's Republic of China PubMed articlesGoogle scholar articles
  • Yu Long Department of Nuclear Medicine, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, ChinaHubei Province Key Laboratory of Molecular Imaging, Wuhan, ChinaKey Laboratory of Biological Targeted Therapy, the Ministry of Education, Wuhan, People's Republic of China PubMed articlesGoogle scholar articles
  • Nannan Wei Department of Nuclear Medicine, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, ChinaHubei Province Key Laboratory of Molecular Imaging, Wuhan, ChinaKey Laboratory of Biological Targeted Therapy, the Ministry of Education, Wuhan, People's Republic of China PubMed articlesGoogle scholar articles
  • Yan Wang Department of Oncology, Liyuan Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China PubMed articlesGoogle scholar articles
  • Ziyang Zhu Department of Nuclear Medicine, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, ChinaHubei Province Key Laboratory of Molecular Imaging, Wuhan, ChinaKey Laboratory of Biological Targeted Therapy, the Ministry of Education, Wuhan, People's Republic of China PubMed articlesGoogle scholar articles
  • Jinquan Han Wuhan-Britain China School, Wuhan, China PubMed articlesGoogle scholar articles
  • Dawei Jiang Department of Nuclear Medicine, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, ChinaHubei Province Key Laboratory of Molecular Imaging, Wuhan, ChinaKey Laboratory of Biological Targeted Therapy, the Ministry of Education, Wuhan, People's Republic of China PubMed articlesGoogle scholar articles
  • Xiaoli Lan Department of Nuclear Medicine, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, ChinaHubei Province Key Laboratory of Molecular Imaging, Wuhan, ChinaKey Laboratory of Biological Targeted Therapy, the Ministry of Education, Wuhan, People's Republic of China PubMed articlesGoogle scholar articles
  • Yongkang Gai Department of Nuclear Medicine, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, ChinaHubei Province Key Laboratory of Molecular Imaging, Wuhan, ChinaKey Laboratory of Biological Targeted Therapy, the Ministry of Education, Wuhan, People's Republic of China PubMed articlesGoogle scholar articles

Citation

Yuan P, Long Y, Wei N, et al
Peptide-based PET tracer targeting LAG-3 for evaluating the efficacy of immunotherapy in melanoma
Journal for ImmunoTherapy of Cancer 2024;12:e009010. doi: 10.1136/jitc-2024-009010
Online issue publication 
July 23, 2024

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Copyright information

© Author(s) (or their employer(s)) 2024. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ. http://creativecommons.org/licenses/by-nc/4.0/This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See http://creativecommons.org/licenses/by-nc/4.0/.